Risk of a second neoplasm associated with selected characteristics of patients and therapeutic exposures (multivariate analysis)
| Characteristics . | RR (95% CI) . | ||||
|---|---|---|---|---|---|
| All second neoplasms (n = 63) . | Solid tumors (n = 39) . | Brain tumors (n = 19) . | AML/MDS (n = 14) . | NHL (n = 6) . | |
| Age at diagnosis of ALL | |||||
| 0-5 y | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| More than 5 y | 1.1 (0.7-1.7) | 0.9 (0.5-1.7) | 0.6 (0.2-1.5) | 1.3 (0.5-3.7) | 1.4 (0.3-6.8) |
| Sex | |||||
| Male | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Female | 1.8 (1.1-2.8)5-150 | 2.9 (1.5-5.8)5-150 | 2.5 (0.9-6.4) | 0.8 (0.3-2.3) | 0.6 (0.1-3.5) |
| Cyclophosphamide dose | |||||
| None | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1-2000 mg/m2 | 1.2 (0.6-2.2) | 1.8 (0.8-4.3) | 0.7 (0.2-2.6) | 5.7 (0.7-46.9) | 0.8 (0.1-5.6) |
| More than 2000 mg/m2 | 1.4 (0.7-2.7) | 1.6 (0.6-3.9) | 0.9 (0.3-2.9) | 5.8 (0.7-48.3) | 0.9 (0.1-6.3) |
| Anthracycline dose | |||||
| None | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1-200 mg/m2 | 1.2 (0.4-2.3) | 1.5 (0.7-3.6) | 0.6 (0.2-1.9) | 5.7 (0.7-44.6) | 0.6 (0.1-1.5) |
| More than 200 mg/m2 | 1.4 (0.6-3.3) | 2.4 (0.8-6.9) | 1.8 (0.5-6.5) | 5.9 (0.5-65.7) | Nonconvergent |
| Radiation | |||||
| No radiation given | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Radiation given | 1.6 (1.0-2.6)5-150 | 2.5 (1.2-5.5)5-150 | 2.4 (1.1-5.2)5-150 | 1.3 (0.5-3.8) | 0.3 (0.1-2.8) |
| Radiation dose | |||||
| None | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1800 cGy | 1.5 (0.9-2.6) | 2.8 (1.5-5.6)5-150 | 2.1 (0.7-6.3) | 1.6 (0.5-4.8) | 0.6 (0.2-2.3) |
| 2400 cGy | 3.9 (1.4-11.2)5-150 | 5.8 (1.3-25.3)5-150 | 4.2 (0.5-37.7) | 4.4 (0.6-36.1) | 3.6 (0.5-28.2) |
| Relapse of primary disease | |||||
| No | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Yes | 3.5 (2.1-5.8)5-150 | 3.1 (1.6-6.1)5-150 | 2.5 (0.9-7.6)5-151 | 3.4 (1.2-9.8)5-150 | 2.2 (0.4-11.8) |
| Characteristics . | RR (95% CI) . | ||||
|---|---|---|---|---|---|
| All second neoplasms (n = 63) . | Solid tumors (n = 39) . | Brain tumors (n = 19) . | AML/MDS (n = 14) . | NHL (n = 6) . | |
| Age at diagnosis of ALL | |||||
| 0-5 y | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| More than 5 y | 1.1 (0.7-1.7) | 0.9 (0.5-1.7) | 0.6 (0.2-1.5) | 1.3 (0.5-3.7) | 1.4 (0.3-6.8) |
| Sex | |||||
| Male | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Female | 1.8 (1.1-2.8)5-150 | 2.9 (1.5-5.8)5-150 | 2.5 (0.9-6.4) | 0.8 (0.3-2.3) | 0.6 (0.1-3.5) |
| Cyclophosphamide dose | |||||
| None | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1-2000 mg/m2 | 1.2 (0.6-2.2) | 1.8 (0.8-4.3) | 0.7 (0.2-2.6) | 5.7 (0.7-46.9) | 0.8 (0.1-5.6) |
| More than 2000 mg/m2 | 1.4 (0.7-2.7) | 1.6 (0.6-3.9) | 0.9 (0.3-2.9) | 5.8 (0.7-48.3) | 0.9 (0.1-6.3) |
| Anthracycline dose | |||||
| None | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1-200 mg/m2 | 1.2 (0.4-2.3) | 1.5 (0.7-3.6) | 0.6 (0.2-1.9) | 5.7 (0.7-44.6) | 0.6 (0.1-1.5) |
| More than 200 mg/m2 | 1.4 (0.6-3.3) | 2.4 (0.8-6.9) | 1.8 (0.5-6.5) | 5.9 (0.5-65.7) | Nonconvergent |
| Radiation | |||||
| No radiation given | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Radiation given | 1.6 (1.0-2.6)5-150 | 2.5 (1.2-5.5)5-150 | 2.4 (1.1-5.2)5-150 | 1.3 (0.5-3.8) | 0.3 (0.1-2.8) |
| Radiation dose | |||||
| None | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1800 cGy | 1.5 (0.9-2.6) | 2.8 (1.5-5.6)5-150 | 2.1 (0.7-6.3) | 1.6 (0.5-4.8) | 0.6 (0.2-2.3) |
| 2400 cGy | 3.9 (1.4-11.2)5-150 | 5.8 (1.3-25.3)5-150 | 4.2 (0.5-37.7) | 4.4 (0.6-36.1) | 3.6 (0.5-28.2) |
| Relapse of primary disease | |||||
| No | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Yes | 3.5 (2.1-5.8)5-150 | 3.1 (1.6-6.1)5-150 | 2.5 (0.9-7.6)5-151 | 3.4 (1.2-9.8)5-150 | 2.2 (0.4-11.8) |